U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene

Contributed by: Business Wire

Logo

Tags

Oncology

Professional Services

Patent Law

Health

Genetics

Pharmaceutical

Biotechnology

USPTO decision

More Like This

(Graphic: Business Wire)

BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference

BeiGene Announces First Quarter 2025 Financial Results and Business Updates

BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024

BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference

BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets